English  |  正體中文  |  简体中文  |  Items with full text/Total items : 62796/95837 (66%)
Visitors : 3641401      Online Users : 327
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/115219


    Title: Effect of Proton Pump Inhibitors in Hospitalization on Mortality of Patients with Hepatic Encephalopathy and Cirrhosis but no Active Gastrointestinal Bleeding
    Authors: Tsung-Hsing Hung;Hsing-Feng Lee;Chih-Wei Tseng;Chih-Chun Tsai;Chen-Chi Tsai
    Keywords: Cirrhosis;Hepatic encephalopathy;Proton pump inhibitor;Mortality
    Date: 2018-09
    Issue Date: 2018-10-18 12:10:45 (UTC+8)
    Publisher: Elsevier
    Abstract: Hepatic encephalopathy (HE) is a neuropsychiatric complication of decompensated cirrhosis. Proton pump inhibitors (PPIs), used as potent acid suppressants, are associated with HE occurrence in cirrhotic patients. However, it is still unknown if PPIs contribute to mortality in cirrhotic patients with HE and no active gastrointestinal bleeding.
    We used the Taiwan National Health Insurance Database to identify 1004 cirrhotic patients with HE and no active gastric bleeding, who received oral PPIs between January 1, 2010 and December 31, 2013. On the basis of comorbid disorder data, we used propensity score matching at a 1:4 ratio to select 4016 cirrhotic patients with HE and no active gastric bleeding who did not receive PPIs as a comparison group. All patients were followed up for one year from the index time.
    The overall 30-day, 90-day, and 1-year mortalities were 36.1%, 52.6%, and 70.1% in PPI group, and 27.5%, 41.7%, and 62.4% in non-PPI group. Using Cox regression model analysis with adjustment for age, gender, and other comorbid disorders, we obtained hazard ratios of 1.360 (95% CI: 1.208–1.532, P < 0.001), 1.563 (95% CI: 1.314–1.859; P < 0.001), and 1.187 (95% CI: 1.008–1.398; P = 0.040) for, respectively, 30-day, 30-day to 90-day, and 90-day to 1-year mortality in patients taking PPIs.
    Relation: Clinics and Research in Hepatology and Gastroenterology 42(4), p.353-359
    DOI: 10.1016/j.clinre.2017.11.011
    Appears in Collections:[數學學系暨研究所] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML147View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback